Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Dr. Tolaney Discusses Unmet Needs in ER+ Breast Cancer
August 31st 2018Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses unmet needs in the treatment of patients with estrogen receptor (ER)-positive breast cancer.
Dr. Krop on the Impact of Recent Advances in Breast Cancer
August 30th 2018Ian E. Krop, MD, PhD, chief, Breast Oncology, Susan F. Smith Center for Women’s Cancers, clinical research director, Breast Oncology Center, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the impact of recent advances in breast cancer.
Dr. Munshi on the Role of Checkpoint Inhibitors in Myeloma
August 29th 2018Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the role of checkpoint inhibitors in myeloma.
Dr. Tolaney Discusses the Role of Chemotherapy in HER2+ Breast Cancer
August 22nd 2018Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the role of chemotherapy in the treatment of patients with HER2-positive breast cancer.
Dr. Matulonis Discusses QoL Data from GOG-258 in Endometrial Cancer
August 17th 2018Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the quality-of-life outcomes from the GOG-258 trial in patients with endometrial cancer.
Dr. Munshi on Latest Treatment Developments in Multiple Myeloma
August 16th 2018Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the latest treatment developments for patients with multiple myeloma.
Dr. Ligibel on Patient Education to Avoid Breast Cancer Recurrence
August 15th 2018Jennifer Ligibel, MD, senior physician, Susan F. Smith Center for Women's Cancer at the Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the resources available for patients to educate themselves on avoiding breast cancer recurrence.
Dr. Tolaney on Selecting Patients for CDK4/6 Inhibitors in Breast Cancer
August 9th 2018Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses selecting patients with estrogen receptor (ER)-positive breast cancer for treatment with CDK4/6 inhibitors.
Dr. Chi Discusses Tazemetostat Trial in INI1-Negative Pediatric Tumors
August 9th 2018Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses a trial of tazemetostat in pediatric patients with INI1-negative tumors.
Dr. Konstantinopoulos on Rationale for TOPACIO Trial in Ovarian Cancer
July 25th 2018Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the rationale behind the TOPACIO trial for the treatment of patients with recurrent ovarian cancer.
Dr. Chi Discusses Pediatric Atypical Teratoid Rhabdoid Tumors
July 23rd 2018Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses pediatric atypical teratoid rhabdoid tumors.
Dr. Reardon on Pembrolizumab and Bevacizumab for Glioblastoma
July 23rd 2018David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses pembrolizumab (Keytruda) and bevacizumab (Avastin) for the treatment of patients with recurrent PD-L1–positive glioblastoma.
Dr. Tolaney on Abemaciclib Plus Pembrolizumab for HR+, HER2- Breast Cancer
July 18th 2018Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the phase Ib results of abemaciclib (Verzenio) plus pembrolizumab (Keytruda) for hormone receptor-positive, HER2-negative metastatic breast cancer.
Dr. Choueiri Discusses Checkpoint Inhibitors in RCC
July 4th 2018Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses checkpoint inhibitors in renal cell carcinoma (RCC).
Dr. Fraizer Discusses the MaGIC Consortium
May 29th 2018Lindsay Frazier, MD, institute physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, associate professor of pediatrics, Harvard Medical School, discusses the Malignant Germ Cell International Consortium (MaGIC) in pediatric and rare tumors.